Duchenne Muscular Dystrophy (DMD) Clinical Trial
Official title:
The Validity and Reliability of The Peabody Developmental Motor Score In Children With Preschool Duchenne Muscular Dystrophy
NCT number | NCT05990608 |
Other study ID # | 2021/371 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | July 30, 2021 |
Est. completion date | July 30, 2023 |
Verified date | August 2023 |
Source | Ondokuz Mayis University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
To perform the reliability and validity study of the Peabody Developmental Motor Scale (Peabody Developmental Motor Scales-2) in children with Duchenne Muscular Dystrophy (DMD).
Status | Completed |
Enrollment | 48 |
Est. completion date | July 30, 2023 |
Est. primary completion date | July 30, 2022 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 3 Years to 5 Years |
Eligibility | Inclusion Criteria: - for Group I: - No neurodevelopmental problems or diseases - 3-5 years old - Being able to cooperate with the instructions given by the physiotherapist. - Children who volunteered to participate in the study and whose families gave consent form will be included in the study. - for Group II: - Being diagnosed with Duchenne Muscular Dystrophy by a pediatric neurologist - 3-5 years old - Children who volunteered to participate in the study and whose parents' consent was obtained will be included in the study. Exclusion Criteria: - Children with a behavioral condition and any disorder that interferes with testing (eg autism spectrum disorder) - Failure to cooperate with the physiotherapist who made the evaluations. - Lack of volunteers. |
Country | Name | City | State |
---|---|---|---|
Turkey | Ondokuz Mayis University | Samsun |
Lead Sponsor | Collaborator |
---|---|
Ondokuz Mayis University |
Turkey,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Peabody Developmental Motor Scales-2 | This assessment will take place over the course of the study started and to the finish time |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT02814019 -
A Phase III Double-blind Study With Idebenone in Patients With Duchenne Muscular Dystrophy (DMD) Taking Glucocorticoid Steroids
|
Phase 3 | |
Completed |
NCT01478022 -
To Compare the Pharmacokinetics Profiles of ISO 20, IBU 200 and IBU Plus ISO Combinations 200 + 20
|
Phase 1 | |
Completed |
NCT00654784 -
Efficacy and Tolerability of Idebenone in Boys With Cardiac Dysfunction Associated With Duchenne Muscular Dystrophy
|
Phase 2 | |
Recruiting |
NCT02614820 -
The Safety, Efficacy and Tolerability of Remote Ischemic Preconditioning as a Therapy to DMD
|
N/A | |
Withdrawn |
NCT02036463 -
A Trial of Chronotherapy of Corticosteroids in Duchenne Muscular Dystrophy
|
Phase 2 | |
Completed |
NCT02255552 -
Study of Eteplirsen in DMD Patients
|
Phase 3 | |
Completed |
NCT01982695 -
Cardiomyopathy in DMD: Lisinopril vs. Losartan
|
N/A | |
Recruiting |
NCT05516745 -
E-monitoring of PULMonary Function in Patients With Duchenne Muscular Dystrophy at Home"
|
N/A | |
Completed |
NCT02420379 -
Safety Study of Eteplirsen to Treat Early Stage Duchenne Muscular Dystrophy
|
Phase 2 | |
Active, not recruiting |
NCT05135663 -
Extension Study of NS-089/NCNP-02 in DMD
|
Phase 2 | |
Completed |
NCT01380964 -
Research of Biomarkers in Duchenne Muscular Dystrophy Patients
|
N/A | |
Recruiting |
NCT04322357 -
Twice Weekly Steroids and Exercise as Therapy for DMD
|
Phase 2 | |
Not yet recruiting |
NCT06392724 -
A Study to Evaluate the Safety and Tolerability of GEN6050X in Duchenne Muscular Dystrophy.
|
Early Phase 1 | |
Completed |
NCT01540409 -
Efficacy, Safety, and Tolerability Rollover Study of Eteplirsen in Subjects With Duchenne Muscular Dystrophy
|
Phase 2 | |
Terminated |
NCT04184882 -
A Study to Assess the Safety, Tolerability and Preliminary Efficacy of ASP0367 (MA-0211) in Pediatric Male Participants With Duchenne Muscular Dystrophy (DMD)
|
Phase 1 | |
Terminated |
NCT04254172 -
A Low Interventional Study to Monitor Activity Using Wearable Sensors in Duchenne Muscular Dystrophy
|
||
Recruiting |
NCT05524883 -
Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-251 in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping
|
Phase 1/Phase 2 | |
Completed |
NCT01761292 -
A Study to Assess Safety/Tolerability, pk, Effects on Histology, Clinical Parameters of Givinostat in Children With DMD
|
Phase 1/Phase 2 |